Parker Waichman LLP Takes Legal Action Over Eye Risks Linked to Ozempic Drug

On September 8, 2025, Parker Waichman LLP, a prominent national law firm, filed a lawsuit in New Jersey state court representing a Baltimore resident who developed a serious eye condition known as non-arteritic anterior ischemic optic neuropathy (NAION) after taking Ozempic. This lawsuit is part of a broader pattern as the firm has been actively pursuing similar legal actions on behalf of numerous patients facing irreversible eye injuries attributed to the popular diabetes and weight-loss medication.

The Dangers of Ozempic

Ozempic, which contains the active ingredient semaglutide, was initially developed to treat Type 2 diabetes but has gained popularity for its weight-loss effects. However, recent studies have raised alarms about the drug's association with NAION—a condition that can lead to complete or partial vision loss.

In a startling 2025 study published in JAMA Ophthalmology, several cases of optic nerve disorders linked to GLP-1 medications, including Ozempic, were reported. Most patients exhibited symptoms similar to those seen in NAION. Furthermore, a study conducted by Harvard's Mass Eye and Ear Institute revealed that diabetic patients using semaglutide had a fourfold increased risk, while non-diabetic users faced a staggering sevenfold increased risk of developing NAION.

Despite the emerging evidence, the manufacturer, Novo Nordisk, has not furnished adequate warnings to doctors or patients regarding the potential eye risks associated with these medications. This has fueled the frustration of advocates and legal representatives like Jason S. Goldstein at Parker Waichman LLP, who stresses the gravity of such injuries and the necessity for accountability. Goldstein remarked, "NAION is a devastating, permanent eye injury attributable to semaglutide, yet Novo Nordisk continues to deny the reality of this situation by failing to properly inform the public and medical community of the risks."

Advocating for Victims Nationwide

Parker Waichman LLP has expanded their investigation into cases of vision loss where plaintiffs have used either Ozempic or its sister drug, Wegovy. The firm is actively seeking individuals who have experienced sudden vision changes or complete loss after taking these medications to seek compensation for medical expenses, lost income, pain and suffering, and other related damages.

The serious implications of this lawsuit go beyond individual cases; they point to a significant public health issue. Legal representatives at Parker Waichman LLP encourage victims to come forward and seek a free case evaluation, as affected individuals may be entailed to substantial compensation designed to offset losses incurred through their injuries. For those who have suffered severe eye injuries following the use of these drugs, immediate legal counsel is recommended.

How to Get Involved

If you or someone you know has suffered vision impairment after using Ozempic or Wegovy, you are urged to contact Parker Waichman LLP for a complimentary, no-obligation case evaluation. Their team is equipped to assist you in navigating the complexities of legal processes surrounding pharmaceutical liability. You can reach them at 1-800-YOUR-LAWYER (1-800-968-7529) or visit their website at www.yourlawyer.com for more information.

About Parker Waichman LLP

With a distinguished history of fighting for the rights of victims affected by defective medications and corporate negligence, Parker Waichman LLP has gained national recognition. Their track record includes securing substantial verdicts and settlements for clients suffering from drug-related injuries, including notable cases involving eye health. The firm continues to advocate for those adversely affected by pharmaceutical defects, ensuring that justice is pursued on every front.